Effectiveness of Reminiscence Therapy Versus Cognitive Stimulation in Older Adults With Cognitive Decline: a Quasi-experimental Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cognitive Decline
- Sponsor
- Paulo Costa
- Enrollment
- 106
- Locations
- 1
- Primary Endpoint
- Change in cognition (person with cognitive decline)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Although data suggest that non-pharmacologic therapies such as Reminiscence Therapy (RT) and Cognitive Stimulation (CS) can potentially maintain or reverse this trend, cognitive impairment can be a precursor to neurodegenerative processes. This study aimed to assess how an RT and a CS program affected cognition, depressive symptomatology, and quality of life (QoL) in older persons with cognitive decline who attended community support institutions in central Portugal. For seven weeks, a quasi-experimental study with two arms (RT and CS program) was conducted. The intervention was completed by 76 of the 109 older persons who were first screened (50 in the RT program, 26 in the CS program). In both groups, a pre- and post-intervention analysis revealed statistically significant differences in cognition, particularly in older adults' delayed recall ability.
Investigators
Paulo Costa
Researcher
Escola Superior de Enfermagem de Coimbra
Eligibility Criteria
Inclusion Criteria
- •Ability to give informed consent before study commencement;
- •Ability to participate in group activities for a period between 45 to 60 minutes;
- •No pronounced impairment of their visual and auditory abilities;
- •Mild to moderate cognitive decline, assessed as a score equal to or below 20 points in the Six-Item Cognitive Impairment Test (6-CIT).
Exclusion Criteria
- •Unstable clinical condition;
- •Prescribed with cholinesterase inhibitors and/or antipsychotics during the study period.
Outcomes
Primary Outcomes
Change in cognition (person with cognitive decline)
Time Frame: 8 weeks post baseline
Measured using the Montreal Cognitive Assessment (MoCA). Scale scores vary between 0 and 30 points; higher scores correspond to a higher cognition level.
Change in depressive dymptomatology (person with cognitive decline)
Time Frame: 8 weeks post baseline
Measured using the 10-items Geriatric Depression Scale (GDS-10). Scale scores vary between 0 and 10 points; scores equal or above 2 points correspond to a screening diagnosis of depression.
Change in quality of life (person with cognitive decline)
Time Frame: Pre-intervention (baseline), 8 weeks post baseline
Measured using the World Health Organization Quality of Life - module for older adults (WHOQOL-OLD-8). Scale scores vary between 8 and 40 points; higher scores correspond to a higher level of quality of life.